Black Rock Inc. Gt Biopharma, Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.24 - $0.35 $183 - $267	-763 Reduced 0.25%	304,041 $72,000
Q2 2023 Aug 11, 2023	SELL	$0.22 - $0.55 $15,456 - $38,641	-70,257 Reduced 18.73%	304,804 $94,000
Q1 2023 May 12, 2023	BUY	$0.46 - $1.05 $1,043 - $2,381	2,268 Added 0.61%	375,061 $206,000
Q4 2022 Feb 13, 2023	BUY	$0.89 - $58.2 $903 - $59,073	1,015 Added 0.27%	372,793 $331,000
Q3 2022 Nov 14, 2022	SELL	$1.81 - $56.1 $8,644 - $267,933	-4,776 Reduced 1.27%	371,778 $654,000
Q2 2022 Aug 12, 2022	SELL	$1.64 - $3.11 $1.27 Million - $2.41 Million	-774,675 Reduced 67.29%	376,554 $1.13 Million
Q1 2022 May 12, 2022	SELL	$2.6 - $3.3 $38,472 - $48,830	-14,797 Reduced 1.27%	1,151,229 $3.32 Million
Q4 2021 Feb 10, 2022	BUY	$3.05 - $7.08 $32,933 - $76,449	10,798 Added 0.93%	1,166,026 $3.56 Million
Q3 2021 Nov 09, 2021	SELL	$6.68 - $15.26 $1.72 Million - $3.94 Million	-258,163 Reduced 18.27%	1,155,228 $7.79 Million
Q2 2021 Aug 11, 2021	BUY	$7.19 - $18.96 $10.2 Million - $26.8 Million	1,413,391 New	1,413,391 $21.9 Million

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $81.7M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.